Инсулинорезистентность и повышение артериального давления – две цели антигипертензивной терапии


С.В. Недогода

Волгоградский государственный медицинский университет, Волгоград
В обзоре обсуждается проблема патогенетической связи инсулинорезистентности (ИР) и артериальной гипертензии (АГ). Ведущими факторами возникновения ИР наряду с генетически детерминированной ИР в 50 % случаев являются стресс, переедание, ожирение и гиподинамия. Представлены механизмы развития тканевой ИР, показана роль ИР в патогенезе АГ и требования к антигипертензивной терапии, которые необходимо соблюдать при лечении АГ на фоне ИР. Дана сравнительная характеристика основных классов антигипертензивных препаратов, применяемых с этой целью.

Литература


1. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation.European Group for the Study of Insulin Resistance (EGIR). Diabet. Med 1999; 16:442–43.
2. Barath A, Tun S, Nemeth I, et al. The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatr. Nephrol 2006;10(21):1419–25.
3. Baxter JD, Young WF, Webb PL. Cardiovascular Endocrinology: Introduction. Endocrine Rev 2003;24(3):253–60.
4. Bonin-Guillaume S, Herrmann FR, Boillat D, et al. Insulinemia and leptinemia in geriatric patients: markers of the metabolic syndrome or of undernutrition? Arq Bras Endocrinol Metab 2006;2(50)304–12.
5. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004;89(8): 3943–48.
6. Cesaretti ML, Kohlmann O Jr. Experimental models of insulin resistance and obesity: lessons
learned. Arq Bras Endocrinol Metab 2006;2(50):190–97.
7. Correia ML, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006;8(6):603–10.
8. D`Orazio N. Obesity and immune function. Ann Ital Chir 2005;5(76):413–16.
9. Dubinski A, Zdrojewicz Z. The role of leptin in the development of hypertension. Hig. Med Dosw 2006;60:447–52.
10. Ernsberger P, Friedman JE, Koletsky RJ. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997;15(l):S9–23.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
12. Fabian E, Varga A, Picano E, et al. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Amer J Cardiol 2004; 94:652–55.
13. Francischetti EA, Genelhu VA. Obesityhypertension: an ongoing pandemic. Intern J Clin Pract 2007;2(6):269–80.
14. Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator
of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 2007;50(1):8–17.
15. Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab 2004;89(9):4206–10.
16. Grundy SМ, Brewer HB Yr, et al. National Heart, Lung, and Blood Institute, American College
of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;109:433–38.
17. Guzder RN, Gatling W, Mullee MA, Burne CD. Impact of metabolic syndrome criteria on cardiovascular
disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006;49(11):49–55.
18. Ihara S, Shimamoto К, Watanabe H, et al. An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. Hypertens Res 2006;10(29):805–11.
19. International Diabetes Federation. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition. – 2005.
20. Knouff C, Auwerx J. Peroxisome proliferatoractivated receptor-γ calls for activation in moderation:
lessons from genetics and pharmacology. Endocrine Rev 2005;25(6):899–918.


21. Koletsky RJ, Velliquette RA, Ernsberger P. The role of I(1)-imidazoline receptors and of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann NY Acad Sci 2003;1009:251–61.
22. Lara-Castro C, Garvey T. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab 2004;89(9):4197–205.
23. Lavoie JL, Sigmund C. Minireview: overview of the renin-angiotensin system – an endocrine and paracrine system. Endocrinology 2003;144(6):2179–83.
24. Lawlor DА, Davey Smith G, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Diabetologia 2006;49(11):41–48.
25. Lee C-H, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144(6):2201–07.
26. Liu Y-M, Moldes M, Bastard J-P, et al. Adiponutrin: a new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab 2004;89(6):2684–89.
27. Mlinar B, Marc J, Janez A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007; 1–2(375):20–35.
28. Muller M, den Tonkelaar I, Thijssen J HH, et al. Endogenous sex hormones in men aged 40–80 years. Eur J Endocrinology 2003;149:583–89.
29. Neel JV. Diabetes Mellitus: A Thrifty Genotype Rendered Detrimental by Progress? Am J Hum Genet 1962;14(4):353–62.
30. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004;89(9):4221–26.
31. Poulsen P, Vaag A. Glucose and insulin metabolism in twins: influence of zygosity and birth weight. Twin Res 1999;319(7203):151–54.
32. Rayner B. Advances in the treatment of diabetic renal disease: focus on losartan. Curr Med Res Opin 2004;3(20):359–67.
33. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.
34. Reid JL. Update on rilmenidine: clinical benefits. Amer J Hypertens 2000;3(6 Pt 2):106–07.
35. Sanjuliani AF, de Abreu VG, Francischetti LA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Intern J Clin Pract 2006;60(5):621–29.
36. Schmidt MI, Duncan BB, Vigo A, et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006;9(49):2086–96.
37. Shi Y, Taylor S, Tan S-L, Sonenberg N. When translation meets metabolism: multiple links to diabetes. Endocrine Reviews 2003: 24(1):91–101.
38. Spinar J, Vitovec J. Imidazole receptor agonists a new advance in the treatment of hypertension?
Vnitr Lek 2000;2(46):122–25.
39. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522–25.
40. Stock S, Leichner P, Wong AC K. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. Clin Endocrinol 2002;56:203–06.
41. Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with
increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007;45(18):154–65.
42. Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive
agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 2006;4(372):300–12.
43. Vilarrasa N, Vendrell J, Maravall Jб et al. IL-18: relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res 2006;8(38): 507–12.
44. Wasim H, Al-Daahri NM, Cherry R, et al. Relationship of serum adiponectin and resistin
to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol 2006;2:5–10.
45. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance, 1999.


Об авторах / Для корреспонденции


Недогода С.В. – д.м.н., проф., проректор по лечебной работе, зав кафедрой терапии и семейной медицины ФУВ Волгоградский медицинский университет. E-mail: nedogodasv@rambler.ru


Похожие статьи


Бионика Медиа